# Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis

> **NCT06926569** · NA · NOT_YET_RECRUITING · sponsor: **Shanghai Public Health Clinical Center** · enrollment: 116 (estimated)

## Conditions studied

- HIV/AIDS-associated Talaromycosis

## Interventions

- **DRUG:** Amphotericin B
- **DRUG:** AmBisome

## Key facts

- **NCT ID:** NCT06926569
- **Lead sponsor:** Shanghai Public Health Clinical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2026-01-05
- **Final completion:** 2026-05-01
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2025-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06926569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06926569, "Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06926569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*